2024
Impact of Synthetic PET Evaluation prior to PET-Guided Functional Modeling in Optimizing Patient Selection for Biology-Guided Radiotherapy
Hicks D, Chen H, Kim J, Tressel L, Wallington D, Becht K, Johung K, Young M, Feghali K, de Jong D, Chen Z, Carlson D, Park H. Impact of Synthetic PET Evaluation prior to PET-Guided Functional Modeling in Optimizing Patient Selection for Biology-Guided Radiotherapy. International Journal Of Radiation Oncology • Biology • Physics 2024, 120: s162-s163. DOI: 10.1016/j.ijrobp.2024.07.2188.Peer-Reviewed Original ResearchPlanning target volumeInternal target volumeBiology-guided radiotherapyStereotactic body radiotherapyGross tumor volumeTarget volumeCT simulationOptimal patient selectionPET evaluationStereotactic body radiotherapy planLung target volumesPatient selectionPTV edgesLung casesBgRTPET-CTTumor sizeTumor volumeRadiotherapyCase 2PET dataLungActivity concentrationsPatientsConsistent with resultsEvaluation of Biology-Guided Radiotherapy (BgRT) in Motion Phantom with Real Patient Breathing Patterns
Chen H, Han D, Draeger E, Zhong W, Lee M, Guan F, Hicks D, Park H, Johung K, Young M, Bal G, Carlson D, Chen Z. Evaluation of Biology-Guided Radiotherapy (BgRT) in Motion Phantom with Real Patient Breathing Patterns. International Journal Of Radiation Oncology • Biology • Physics 2024, 120: e107. DOI: 10.1016/j.ijrobp.2024.07.2018.Peer-Reviewed Original ResearchGamma passing ratesBiology-guided radiotherapyPatient's breathing patternMotion phantomPass ratePatient-specific quality assuranceBreathing periodPhantom studyGamma passing criteriaTumor motion managementAssess target coverageQuality assurance phantomBreathing patternDosimetric accuracyConformity indexMotion managementActivity concentrationsHomogeneity indexTarget coverageDelivery accuracyTarget volumeSpherical targetCommissioning dataBgRTPassing criteriaNCCN Guidelines® Insights: Rectal Cancer, Version 3.2024.
Benson A, Venook A, Adam M, Chang G, Chen Y, Ciombor K, Cohen S, Cooper H, Deming D, Garrido-Laguna I, Grem J, Haste P, Hecht J, Hoffe S, Hunt S, Hussan H, Johung K, Joseph N, Kirilcuk N, Krishnamurthi S, Malla M, Maratt J, Messersmith W, Meyerhardt J, Miller E, Mulcahy M, Nurkin S, Parikh A, Patel H, Pedersen K, Saltz L, Schneider C, Shibata D, Shogan B, Skibber J, Sofocleous C, Tavakkoli A, Willett C, Wu C, Jones F, Gurski L. NCCN Guidelines® Insights: Rectal Cancer, Version 3.2024. Journal Of The National Comprehensive Cancer Network 2024, 22: 366-375. PMID: 39151454, DOI: 10.6004/jnccn.2024.0041.Peer-Reviewed Original ResearchConceptsRectal cancerResponders to neoadjuvant therapyRisk of pelvic recurrenceLocally recurrent rectal cancerEarly-stage rectal cancerNonoperative management approachRecurrent rectal cancerDistal rectal cancerNCCN Guidelines InsightsCurative-intent therapyRectal cancer surgeryOptimal treatment planEndoscopic submucosal dissectionQuality of lifePelvic recurrenceNeoadjuvant therapyMultimodal therapyNCCN GuidelinesGenitourinary functionPatient selectionPoor prognosisCancer surgeryColon cancerSubmucosal dissectionClinical trialsPerioperative Modified FOLFIRINOX for Resectable Pancreatic Cancer
Cecchini M, Salem R, Robert M, Czerniak S, Blaha O, Zelterman D, Rajaei M, Townsend J, Cai G, Chowdhury S, Yugawa D, Tseng R, Arbelaez C, Jiao J, Shroyer K, Thumar J, Kortmansky J, Zaheer W, Fischbach N, Persico J, Stein S, Khan S, Cha C, Billingsley K, Kunstman J, Johung K, Wiess C, Muzumdar M, Spickard E, Aushev V, Laliotis G, Jurdi A, Liu M, Escobar-Hoyos L, Lacy J. Perioperative Modified FOLFIRINOX for Resectable Pancreatic Cancer. JAMA Oncology 2024, 10: 1027-1035. PMID: 38900452, PMCID: PMC11190830, DOI: 10.1001/jamaoncol.2024.1575.Peer-Reviewed Original ResearchProgression-free survivalPancreatic ductal adenocarcinomaOverall survivalCtDNA levelsPhase 2 nonrandomized controlled trialAnalysis of circulating tumor DNAMedian progression-free survivalResectable pancreatic ductal adenocarcinomaControlled trialsAssess surgical candidacyBaseline ctDNA levelModified 5-fluorouracilResectable pancreatic cancerPancreatic protocol computed tomographyAssociated with recurrenceTumor molecular featuresAggressive malignant tumorKaplan-Meier estimatesRandomized clinical trialsStandard of careCtDNA-positivePreoperative cyclesNonrandomized controlled trialsUnresectable diseaseModified FOLFIRINOXA single arm phase 2 clinical trial of YIV-906 with neoadjuvant concurrent chemo-radiation therapy in patients with locally advanced rectal cancer
Verma N, Johung K, Kortmansky J, Zaheer W, Lacy J, Cecchini M, Stein S, Cheng Y, Lam W, Liu S, Reddy V, Hochster H, Higgins S. A single arm phase 2 clinical trial of YIV-906 with neoadjuvant concurrent chemo-radiation therapy in patients with locally advanced rectal cancer. Journal Of Gastrointestinal Oncology 2024, 15: 1050-1059. PMID: 38989411, PMCID: PMC11231844, DOI: 10.21037/jgo-24-23.Peer-Reviewed Original ResearchColon Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology.
Benson A, Venook A, Adam M, Chang G, Chen Y, Ciombor K, Cohen S, Cooper H, Deming D, Garrido-Laguna I, Grem J, Haste P, Hecht J, Hoffe S, Hunt S, Hussan H, Johung K, Joseph N, Kirilcuk N, Krishnamurthi S, Malla M, Maratt J, Messersmith W, Meyerhardt J, Miller E, Mulcahy M, Nurkin S, Overman M, Parikh A, Patel H, Pedersen K, Saltz L, Schneider C, Shibata D, Shogan B, Skibber J, Sofocleous C, Tavakkoli A, Willett C, Wu C, Gurski L, Snedeker J, Jones F. Colon Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology. Journal Of The National Comprehensive Cancer Network 2024, 22 PMID: 38862008, DOI: 10.6004/jnccn.2024.0029.Peer-Reviewed Original ResearchConceptsMetastatic colorectal cancerColorectal cancerNCCN Clinical Practice GuidelinesSystemic therapy optionsGoal of therapyClinical practice guidelinesNCCN GuidelinesToxicity profileTherapy optionsColon cancerMutation profilesActive drugCancer deathDiagnosed cancerCancerConstituent drugsTherapyPractice guidelinesNCCNDrugTumorColorectalGuidelinesUnited StatesOncology
2023
Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal Cancer
Cecchini M, Zhang J, Wei W, Sklar J, Lacy J, Zhong M, Kong Y, Zhao H, DiPalermo J, Devine L, Stein S, Kortmansky J, Johung K, Bindra R, LoRusso P, Schalper K. Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal Cancer. Cancer Research Communications 2023, 3: 1132-1139. PMID: 37387791, PMCID: PMC10305782, DOI: 10.1158/2767-9764.crc-23-0045.Peer-Reviewed Original ResearchConceptsWhole-exome sequencingMGMT protein expressionColorectal cancerStable diseaseQuantitative immunofluorescenceT cellsProtein expressionPromoter hypermethylationLow MGMT protein expressionPARP inhibitorsRadiographic tumor regressionMetastatic colorectal cancerAdvanced colorectal cancerPretreatment tumor biopsiesEffector T cellsTumor-infiltrating lymphocytesMGMT proteinDNA repair biomarkersBaseline CD8Eligible patientsIncreased CD8Methylguanine-DNA methyltransferaseObjective responseProgressive diseaseImmune markersAnal Carcinoma, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology.
Benson A, Venook A, Al-Hawary M, Azad N, Chen Y, Ciombor K, Cohen S, Cooper H, Deming D, Garrido-Laguna I, Grem J, Hecht J, Hoffe S, Hubbard J, Hunt S, Hussan H, Jeck W, Johung K, Joseph N, Kirilcuk N, Krishnamurthi S, Maratt J, Messersmith W, Meyerhardt J, Miller E, Mulcahy M, Nurkin S, Overman M, Parikh A, Patel H, Pedersen K, Saltz L, Schneider C, Shibata D, Skibber J, Sofocleous C, Stotsky-Himelfarb E, Tavakkoli A, Willett C, Williams G, Algieri F, Gurski L, Stehman K. Anal Carcinoma, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology. Journal Of The National Comprehensive Cancer Network 2023, 21: 653-677. PMID: 37308125, DOI: 10.6004/jnccn.2023.0030.Peer-Reviewed Original ResearchConceptsNCCN Clinical Practice GuidelinesAnal carcinomaClinical practice guidelinesPrimary treatmentPractice guidelinesSquamous cell anal carcinomaCommon histologic formExtrapelvic metastatic diseaseMetastatic anal carcinomaSystemic therapy recommendationsAnal canal cancerCurative-intent treatmentAJCC staging systemNCCN guidelinesPerianal cancerMetastatic diseasePersistent diseaseSystemic therapySurgical treatmentMedical oncologyStaging systemOptimal treatmentClinical evaluationHistologic formsTherapy recommendationsPre-operative chemoradiotherapy with or without induction chemotherapy for operable locally-advanced esophageal cancer
Peters G, Talcott W, Peters N, Dhanasopan A, Lacy J, Cecchini M, Kortmansky J, Stein S, Lattanzi S, Park H, Boffa D, Johung K, Jethwa K. Pre-operative chemoradiotherapy with or without induction chemotherapy for operable locally-advanced esophageal cancer. Journal Of Gastrointestinal Oncology 2023, 14: 1181-1192. PMID: 37435226, PMCID: PMC10331751, DOI: 10.21037/jgo-22-1005.Peer-Reviewed Original ResearchProgression-free survivalMedian progression-free survivalOverall survivalIC-CRTInduction chemotherapySingle-institution retrospective cohort studyPre-operative chemoradiotherapyAdvanced esophageal cancerAdvanced esophageal carcinomaPathologic complete responseRetrospective cohort studyKaplan-Meier methodSubset of patientsProportional hazards regressionCycles of inductionAdenocarcinoma histologyCRT cohortCohort studyComplete responsePathologic responseTreatment cohortsDistant metastasisHazards regressionEsophageal cancerEsophageal carcinoma
2022
Utilization and Outcomes of Radiation in Stage IV Esophageal Cancer
Zhan P, Canavan M, Ermer T, Pichert M, Li A, Maduka R, Kaminski M, Johung K, Boffa D. Utilization and Outcomes of Radiation in Stage IV Esophageal Cancer. JTO Clinical And Research Reports 2022, 3: 100429. PMID: 36483656, PMCID: PMC9722471, DOI: 10.1016/j.jtocrr.2022.100429.Peer-Reviewed Original ResearchStage IV esophageal cancerNational Cancer DatabaseEsophageal cancerCancer DatabaseRadiation doseSurvival advantageMedian total radiation dosePropensity score-matched pairsOutcome of radiationRetrospective cohort studyKaplan-Meier analysisTotal radiation doseAppropriate radiation dosePalliative regimensCohort studyMedian ageRadiation administrationSurvival associationsBetter survivalPatientsLocal controlCancerDosePalliationFurther studiesDosimetric Parameters are Associated with Local Control after SBRT for Colorectal Cancer Lung Metastases
Laird J, Mokhtech M, Johung K, Park H, Jethwa K. Dosimetric Parameters are Associated with Local Control after SBRT for Colorectal Cancer Lung Metastases. International Journal Of Radiation Oncology • Biology • Physics 2022, 114: e431-e432. DOI: 10.1016/j.ijrobp.2022.07.1640.Peer-Reviewed Original ResearchCRC lung metastasesInternal target volumeLung metastasesLocal controlPrescription dosesUnivariate analysisPrescription doseCox proportional hazards regression modelColorectal cancer lung metastasesProportional hazards regression modelsDosimetric parametersRetrospective cohort studyFavorable local controlImproved local controlLocal treatment optionsSingle cancer centerKaplan-Meier methodHazards regression modelsTarget volume dosesMATERIAL/METHODSMetastasis sizePTV D90Dosimetric predictorsMedian doseCohort studyImpact of Dosimetric Parameters on Local Control after SBRT for Pancreatic Cancer
Oh P, Laird J, Johung K. Impact of Dosimetric Parameters on Local Control after SBRT for Pancreatic Cancer. International Journal Of Radiation Oncology • Biology • Physics 2022, 114: e197. DOI: 10.1016/j.ijrobp.2022.07.1113.Peer-Reviewed Original ResearchStereotactic body radiotherapyInternal target volumeUnivariate regression analysisGross tumor volumeOverall survivalLocal controlPancreatic cancerPerformance statusSBRT plansTarget volumeCox proportional hazards modelDosimetric parametersAdvanced unresectable diseaseImproved local controlRetrospective cohort studyUse of chemotherapyGood local controlKaplan-Meier methodPancreatic cancer patientsTarget volume sizeProportional hazards modelHigher gross tumor volumeMATERIAL/METHODSComprehensive dosimetric analysisUnresectable diseaseAnalyzing Resident Perceptions of Current Radiation Oncology Evaluation Methods
Manjunath R, Rajeev-Kumar G, Tendulkar R, Corbin K, Johung K, Evans S, Shinohara E, Buckstein M, Pinnix C, Harkenrider M, Golden D, Hasan Y. Analyzing Resident Perceptions of Current Radiation Oncology Evaluation Methods. International Journal Of Radiation Oncology • Biology • Physics 2022, 114: e6. DOI: 10.1016/j.ijrobp.2022.06.007.Peer-Reviewed Original Research
2021
Preliminary Report Assessing Resident and Faculty Evaluations Across Radiation Oncology Programs
Rajeev-Kumar G, Manjunath R, Harkenrider M, Das P, Tendulkar R, Corbin K, Jagsi R, Marwaha G, Johung K, Evans S, Jawad M, Shinohara E, Komarnicky L, Yeung A, Buckstein M, Golden D, Hasan Y. Preliminary Report Assessing Resident and Faculty Evaluations Across Radiation Oncology Programs. International Journal Of Radiation Oncology • Biology • Physics 2021, 111: e191. DOI: 10.1016/j.ijrobp.2021.07.697.Peer-Reviewed Original ResearchSystems-based practicePatient careInterpersonal communication skillsCore competenciesRadiation oncologyResident evaluationsFaculty evaluationsPersonal qualitiesGraduate Medical Education's six core competenciesPractice-based learningResidency programsEvaluation of facultyACGME core competenciesMedical knowledgeContents of evaluationRO residency programsTeaching skillsFaculty perspectivesOncology ProgramMentoring skillsTypes of questionsCommunication skillsStandardized criteriaAccreditation CouncilPURPOSE/SBRT for the Treatment of Isolated Local Recurrence of Resected Pancreatic Cancer
Morris L, Viehman J, Baclay J, Chang D, Kerans S, Molitoris J, Regine W, Johung K, Jethwa K, Neibart S, Jabbour S, Hallemeier C. SBRT for the Treatment of Isolated Local Recurrence of Resected Pancreatic Cancer. International Journal Of Radiation Oncology • Biology • Physics 2021, 111: e61. DOI: 10.1016/j.ijrobp.2021.07.408.Peer-Reviewed Original ResearchStereotactic body radiation therapyPancreatic ductal adenocarcinomaSurgical resectionFirst recurrenceCumulative incidenceLocal recurrenceDistant metastasisCompletion of SBRTTime of SBRTLow treatment-related toxicityMulti-institutional retrospective analysisDetails of recurrenceGrade 3 toxicityPrior treatment characteristicsInitial surgical resectionR0 resection rateTreatment-related toxicityRisk of progressionIsolated local recurrenceOverall survival estimatesLocal tumor controlSuperior mesenteric arteryBody radiation therapyKaplan-Meier modelOncologic surgical resectionAnalysis of Resident and Faculty Assessment Methods Used by United States Radiation Oncology Residency Programs
Rajeev-Kumar G, Manjunath R, Tendulkar R, Corbin K, Jagsi R, Marwaha G, Johung K, Evans S, Jawad M, Komarnicky-Kocher L, Shinohara E, Yeung A, Buckstein M, Das P, Harkenrider M, Golden D, Hasan Y. Analysis of Resident and Faculty Assessment Methods Used by United States Radiation Oncology Residency Programs. International Journal Of Radiation Oncology • Biology • Physics 2021, 111: e6-e7. DOI: 10.1016/j.ijrobp.2021.05.146.Peer-Reviewed Original Research2021 NCC/CATS/CSTCVS/STM expert consensus on perioperative immunotherapy for esophageal cancer
Kang X, Qin J, Zhang R, Wang Z, Zheng Q, Li Y, Xu J, Huang J, Wang X, Hui Z, Xue L, Mao Y, Li Y, He J, Chen C, Chen H, Chen K, Chen L, Fu M, Fu J, Geng Q, Gong T, Guo S, Han Y, He Y, Hu J, Jiang H, Jiang J, Jiang Y, Kang M, Ma J, Ma S, Liao Y, Li H, Li S, Li Z, Liu S, Liu Y, Qiao G, Tan L, Tian H, Zhao G, Zhao J, Zheng S, Zhou Y, Nilsson M, Schlottmann F, Rosati R, Stefano C, Chiu P, Newman N, Hirahara N, Kim D, Mehta R, Johung K, Cecchini M, Lloyd S, Meredith K. 2021 NCC/CATS/CSTCVS/STM expert consensus on perioperative immunotherapy for esophageal cancer. Annals Of Esophagus 2021, 4: 33-33. DOI: 10.21037/aoe-21-64.Peer-Reviewed Original Research
2020
The Modern Landscape of Gastrointestinal Clinical Trials and Predictors for Success
Peters G, Jethwa K, Miccio J, Johung K. The Modern Landscape of Gastrointestinal Clinical Trials and Predictors for Success. International Journal Of Radiation Oncology • Biology • Physics 2020, 108: e575. DOI: 10.1016/j.ijrobp.2020.07.1769.Peer-Reviewed Original ResearchAssociation of Neoadjuvant Treatment Modality with Negative Margin and Pathologic Downstaging in Patients Undergoing Pancreatic Cancer Resection: A National Cancer Database Analysis
Miccio J, Mokhtech M, Jabbour S, Anker C, Patel T, Park H, Cecchini M, Salem R, Kuntsman J, Stein S, Kortmansky J, Lacy J, Narang A, Herman J, Haddock M, Hallemeier C, Johung K, Jethwa K. Association of Neoadjuvant Treatment Modality with Negative Margin and Pathologic Downstaging in Patients Undergoing Pancreatic Cancer Resection: A National Cancer Database Analysis. International Journal Of Radiation Oncology • Biology • Physics 2020, 108: e662. DOI: 10.1016/j.ijrobp.2020.07.1980.Peer-Reviewed Original ResearchEsophageal Cancer
Peters G, Rutter C, Johung K. Esophageal Cancer. 2020 DOI: 10.1891/9780826155146.0020.Peer-Reviewed Original Research